drugset / Trial / NCT00470613
Safety Study of Infusion of SGT-53 to Treat Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase Ib study as a continuation of the original Phase I protocol. The purpose of this Phase Ib study is to evaluate the safety of a single course of SGT-53 in combination with docetaxel and determine the recommended Phase II doses of SGT-53 and docetaxel in combination for evaluation in subsequent clinical studies for the treatment of solid tumors.
Timeline
- Start
- 2008-02
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 40 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | SGT-53 | Other / unclassified | 2.4 mg | Other |
| Subject | SGT-53 | Other / unclassified | 3.6 mg | Other |